EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY 4.0

First Reported Use of Recombinant Parathyroid Hormone in Kenny–Caffey Syndrome Type 2: A Case Report and Literature Review

Maja Djordjevic Milosevic iD, Anita Skakic iD, Marina Andjelkovic, Angelica Maria Delgado-Vega iD, Håkan Thonberg, Kristel Klaassen iD, Jovana Komazec iD, Bozica Kecman, Nikola Jocic, Erik Björck, Anna Lindstrand iD, Maja Stojiljkovic

Diseases · 03.03.2026 · 14 (3) · 91

DOI: 10.3390/diseases14030091 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 03.03.2026. Verfasst von Maja Djordjevic Milosevic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Mother and Child Healthcare of Serbia "Dr Vukan Cupic", 11070 Belgrade, Serbia. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission (HORIZON-WIDERA-2023-ACCESS-02).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Hypoparathyroidism (HPT) is a disorder caused by the insufficient production of parathyroid hormone (PTH). Its main features include decreased serum calcium, increased serum phosphorus, and abnormal bone modeling. In children, HPT is most commonly due to genetic disorders. Among rare genetic syndromes that can include HPT in their clinical spectrum is Kenny–Caffey syndrome (KCS) type 2. Conventional therapy for HPT primarily consists of oral calcium and active vitamin D metabolites. The major limitation of conventional therapy is hypercalciuria with an increased risk of nephrocalcinosis. However, a subset of patients fails to achieve the desired therapeutic response to conventional treatment; the reasons for this remain incompletely understood in some cases. The failure to achieve therapeutic targets and persistent hypercalciuria are the main indications for considering therapy with recombinant human parathyroid hormone (rhPTH).

Methods

In addition to the review of the literature on rhPTH use in pediatric hypoparathyroidism, the first application of rhPTH in the treatment of genetically caused HPT in a child with Kenny–Caffey syndrome type 2 (KCS2) was described.

Results

In this paper, we present a two-month-old infant who received rhPTH for 14 months. A heterozygous de novo p.Ser541Pro variant in the FAM111A gene was identified through whole-genome sequencing, indicating a diagnosis of KCS2. A biological mechanism linking FAM111A protein function with a more profound disruption of parathyroid development or function was proposed, suggesting that rhPTH therapy may be particularly beneficial in KCS2 cases.

Conclusions

This is the first reported use of rhPTH in a child in Serbia and the first reported use in KCS type 2. By reviewing the literature, we analyzed the conditions in which rhPTH has been used, dosing approaches and durations, requirements for concomitant conventional therapy during rhPTH treatment, and the effects of rhPTH on calciuria. We provide an overview of rhPTH use in children. Additionally, based on the pathogenic genetic variant responsible for KCS2 in our patient, we propose possible etiologic explanations. This work aims to encourage a consideration of rhPTH use in children following its official approval.

Schlagwörter

Stichwörter der Autor:innen

FAM111A geneKenny–Caffey syndrome type 2hypoparathyroidismparathyroid hormone therapytreatment

Autor:innen und Institutionen

  • Institute for Mother and Child Healthcare of Serbia "Dr Vukan Cupic", 11070 Belgrade, Serbia.
  • Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
  • Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 11042 Belgrade, Serbia.
  • Department of Clinical Genetics and Genomics, Karolinska University Hospital, 17164 Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Karolinska Institute, 17176 Stockholm, Sweden.

ORCID-Profile: Maja Djordjevic Milosevic, Anita Skakic, Angelica Maria Delgado-Vega, Kristel Klaassen, Jovana Komazec, Anna Lindstrand

Förderung

  • European Commission (HORIZON-WIDERA-2023-ACCESS-02)

Zitieren

APA

Djordjevic Milosevic, M., Skakic, A., Andjelkovic, M., Delgado-Vega, A. M., Thonberg, H., Klaassen, K., Komazec, J., Kecman, B., Jocic, N., Björck, E., Lindstrand, A., & Stojiljkovic, M. (2026). First Reported Use of Recombinant Parathyroid Hormone in Kenny–Caffey Syndrome Type 2: A Case Report and Literature Review. Diseases, 14(3), 91. https://doi.org/10.3390/diseases14030091

Vancouver

Djordjevic Milosevic M, Skakic A, Andjelkovic M, Delgado-Vega AM, Thonberg H, Klaassen K, et al. First Reported Use of Recombinant Parathyroid Hormone in Kenny–Caffey Syndrome Type 2: A Case Report and Literature Review. Diseases. 2026;14(3):91. doi:10.3390/diseases14030091

BibTeX
@article{DjordjevicMilosevic2026,
  author = {Djordjevic Milosevic, Maja and Skakic, Anita and Andjelkovic, Marina and Delgado-Vega, Angelica Maria and Thonberg, Håkan and Klaassen, Kristel and Komazec, Jovana and Kecman, Bozica and Jocic, Nikola and Björck, Erik and Lindstrand, Anna and Stojiljkovic, Maja},
  title = {First Reported Use of Recombinant Parathyroid Hormone in Kenny–Caffey Syndrome Type 2: A Case Report and Literature Review},
  journal = {Diseases},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {91},
  doi = {10.3390/diseases14030091}
}
Kostenlos starten →